Aerovate Therapeutics Inc (AVTE)

$18.85

+0.05

(+0.27%)

Market is closed - opens 8 PM, 22 Feb 2024

Insights on Aerovate Therapeutics Inc

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 70.3% return, outperforming this stock by 101.0%

Performance

  • $18.20
    $19.44
    $18.85
    downward going graph

    3.45%

    Downside

    Day's Volatility :6.38%

    Upside

    3.03%

    downward going graph
  • $9.41
    $28.43
    $18.85
    downward going graph

    50.08%

    Downside

    52 Weeks Volatility :66.9%

    Upside

    33.7%

    downward going graph

Returns

PeriodAerovate Therapeutics IncSector (Health Care)Index (Russel 2000)
3 Months
29.66%
11.8%
0.0%
6 Months
29.66%
8.6%
0.0%
1 Year
-30.68%
11.4%
-6.3%
3 Years
25.0%
26.9%
-22.0%

Highlights

Market Capitalization
578.6M
Book Value
$4.55
Earnings Per Share (EPS)
-2.74
Wall Street Target Price
32.33
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-32.58%
Return On Equity TTM
-52.96%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-75.1M
Diluted Eps TTM
-2.74
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-2.84
EPS Estimate Next Year
-2.56
EPS Estimate Current Quarter
-0.69
EPS Estimate Next Quarter
-0.69

Analyst Recommendation

Buy
    91%Buy
    8%Hold
    0
    0%Sell
Based on 12 Wall street analysts offering stock ratings for Aerovate Therapeutics Inc(by analysts ranked 0 to 5 stars)
Based on 12 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
11
11
11
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 71.51%

Current $18.85
Target $32.33

Technicals Summary

Sell

Neutral

Buy

Aerovate Therapeutics Inc is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Aerovate Therapeutics Inc
Aerovate Therapeutics Inc
-6.0%
29.66%
-30.68%
25.0%
25.0%
Moderna, Inc.
Moderna, Inc.
-12.75%
-21.69%
-45.66%
-45.42%
349.79%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
0.43%
12.14%
26.84%
105.58%
126.19%
Novo Nordisk A/s
Novo Nordisk A/s
15.13%
30.68%
70.32%
233.88%
389.13%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-4.42%
19.93%
43.82%
95.68%
129.78%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Aerovate Therapeutics Inc
Aerovate Therapeutics Inc
0.88
NA
NA
-2.84
-0.53
-0.33
NA
4.55
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-12.5
-0.22
-0.07
NA
35.32
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
27.55
27.55
1.93
44.91
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
45.26
45.26
4.51
3.29
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
30.4
30.4
0.57
16.74
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Aerovate Therapeutics Inc
Aerovate Therapeutics Inc
Buy
$578.6M
25.0%
0.88
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$33.7B
349.79%
24.73
-38.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$105.2B
126.19%
27.55
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$541.4B
389.13%
45.26
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$109.1B
129.78%
30.4
36.68%

Institutional Holdings

  • RA Capital Management, LLC

    29.87%
  • Sofinnova Ventures

    13.58%
  • TCG Crossover Management, LLC

    7.96%
  • Baker Bros Advisors LP

    7.10%
  • Cormorant Asset Management, LLC

    5.64%
  • Driehaus Capital Management LLC

    4.29%

Company Information

aerovate is a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease. aerovate's initial focus is on advancing av-101, its dry powder inhaled formulation of the drug imatinib for the treatment of pulmonary arterial hypertension, or pah.

Organization
Aerovate Therapeutics Inc
Employees
43
CEO
Mr. Timothy P. Noyes M.B.A.
Industry
Healthcare

FAQs